First human test of Pfizer's new cancer drug begins
NCT ID NCT06870487
Summary
This early-stage study is testing the safety and side effects of a new cancer drug called PF-08046032, both alone and in combination with another immunotherapy drug called sasanlimab. It involves a small group of adults with advanced lymphomas or solid tumors that have spread or worsened despite standard treatments. The main goal is to find safe dose levels and understand how the body processes these drugs before testing their effectiveness against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutchinson Cancer Center.
Seattle, Washington, 98109, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
University of Washington Medical Center- Montlake
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.